Todays Report: Today, Leerink Swann Reiterates Market Perform Rating for Acorda Therapeutics Inc. (ACOR)

Today, Leerink Swann Reiterates Market Perform Rating for Acorda Therapeutics Inc. (ACOR)

Acorda Therapeutics Inc. (NASDAQ:ACOR)‘s stock had its “market perform” rating reissued by Leerink Swann in a report issued on Wednesday.

Several other analysts also recently issued reports on the company. Cowen and Company reissued a “buy” rating and issued a $60.00 price target on shares of Acorda Therapeutics in a report on Thursday, October 27th. Stifel Nicolaus reissued a “buy” rating on shares of Acorda Therapeutics in a report on Thursday, August 25th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Acorda Therapeutics in a report on Thursday, August 25th. Finally, TheStreet downgraded Acorda Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, July 28th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $38.57.

Shares of Acorda Therapeutics (NASDAQ:ACOR) opened at 21.70 on Wednesday. The stock’s market capitalization is $1.00 billion. Acorda Therapeutics has a 52-week low of $16.40 and a 52-week high of $43.63. The firm’s 50-day moving average price is $19.63 and its 200-day moving average price is $23.95.

Acorda Therapeutics (NASDAQ:ACOR) last released its earnings results on Thursday, October 27th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.22. Acorda Therapeutics had a negative return on equity of 1.66% and a negative net margin of 4.38%. The company had revenue of $135.61 million for the quarter, compared to the consensus estimate of $134.01 million. During the same quarter last year, the business posted $0.31 EPS. Acorda Therapeutics’s quarterly revenue was down 8.5% compared to the same quarter last year. Equities analysts forecast that Acorda Therapeutics will post $0.28 earnings per share for the current fiscal year.

In other news, insider Richard P. Batycky sold 2,063 shares of the business’s stock in a transaction on Friday, October 21st. The stock was sold at an average price of $20.30, for a total value of $41,878.90. Following the sale, the insider now owns 45,916 shares of the company’s stock, valued at approximately $932,094.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jane Wasman sold 3,750 shares of the business’s stock in a transaction on Monday, October 3rd. The stock was sold at an average price of $20.78, for a total value of $77,925.00. Following the completion of the sale, the insider now directly owns 105,021 shares in the company, valued at approximately $2,182,336.38. The disclosure for this sale can be found here. 8.00% of the stock is owned by insiders.

Several hedge funds have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD increased its stake in Acorda Therapeutics by 317.7% in the third quarter. Price T Rowe Associates Inc. MD now owns 719,310 shares of the biopharmaceutical company’s stock worth $15,019,000 after buying an additional 547,100 shares in the last quarter. Gotham Asset Management LLC increased its stake in Acorda Therapeutics by 22.6% in the third quarter. Gotham Asset Management LLC now owns 84,796 shares of the biopharmaceutical company’s stock worth $1,771,000 after buying an additional 15,621 shares in the last quarter. Virtus ETF Advisers LLC increased its stake in Acorda Therapeutics by 14.4% in the third quarter. Virtus ETF Advisers LLC now owns 24,177 shares of the biopharmaceutical company’s stock worth $505,000 after buying an additional 3,047 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in Acorda Therapeutics during the third quarter worth approximately $613,000. Finally, Scopia Capital Management LP purchased a new stake in Acorda Therapeutics during the third quarter worth approximately $87,780,000.

Acorda Therapeutics Company Profile

Related posts

Leave a Comment